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Oral Challenge with Trimethoprim-Sulfamethoxazole in Patients with “Sulfa” Antibiotic 43 
Allergy 44 
 45 
Clinical Implications:  For patients with a non-severe immediate or delayed history of an 46 
unspecified sulfa or TMP-SMX allergy and an upcoming need for treatment or 47 
prophylaxis, direct oral challenge with TMP-SMX is a safe and efficacious procedure. 48 
 49 
To the Editor: “Sulfa” antibiotic allergy is the second most commonly reported class of 50 
outpatient antibiotic allergy.1  The “sulfa” allergy label subsequently limits use of trimethoprim-51 
sulfamethoxazole, (TMP-SMX), which is a preferred agent for methicillin-resistant 52 
Staphylococcus aureus (MRSA) and Pneumocystis jirovecii pneumonia (PJP) prophylaxis.2  53 
Non-antibiotic sulfa containing drugs are not cross-reactive with sulfonamide antibiotics and 54 
importantly differ from sulfonamide antibiotics by the absence of an arylamine group linked to 55 
the benzene ring at N4 and an aromatic 5 or 6 member ring attached to the sulfonamide core as 56 
an N1 substituent.3,4 57 
 58 
Although most reported reactions to sulfonamide antibiotics are non-IgE-mediated, severe T-cell 59 
mediated reactions such as drug rash with eosinophilia and systemic symptoms (DRESS), 60 
Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), acute generalized 61 
exanthematous pustulosis (AGEP), and drug induced nephritis or hepatitis do occur and are strict 62 
contraindications to future TMP-SMX use.5 Current guidelines to manage TMP-SMX treatment 63 
in patients with mild to moderate skin rash without systemic features include desensitization 64 














allergy.  So, if patients require TMP-SMX subsequently, they would need to be desensitized 66 
again.6  The safest and most efficacious approach to rechallenge with sulfonamide antibiotics in 67 
non-HIV infected labeled patients is largely unknow; however, common practice includes 68 
multiple dose rechallenge over several hours.   We examined the safety and outcomes of single 69 
or two dose TMP-SMX oral challenges in adults whose hi tory was inconsistent with a severe 70 
delayed immune mediated reaction, and their subsequent tolerance of future TMP-SMX 71 
treatment. 72 
 73 
Our study presents a retrospective cohort study done under institutional review board (IRB) 74 
approved protocols from Vanderbilt University Medical Center (VUMC), IRB #161455.   75 
Between October 2015 and February 2019, 204 sequential pa ients with history-based past 76 
immediate, non-severe delayed, or unknown reactions o TMP-SMX or unspecified “sulfa” 77 
antibiotics with ongoing avoidance of TMP-SMX underw nt direct observed oral challenges 78 
with TMP-SMX in a dedicated outpatient drug allergy clinic at VUMC.  Patients with any 79 
history of a severe delayed immune mediated reaction, such as SJS, TEN, DRESS, AGEP, or 80 
drug induced nephritis or hepatitis, were excluded (Table E1, available in this article’s Online 81 
Repository at www.jaci-inpractice.org). Patients were selected to receive a two dose TMP-SMX 82 
(8-40mg;80-400mg) challenge with a one-hour observation interval in between if they met the 83 
following criteria:  1) History of multiple cutaneous, respiratory or cardiovascular symptoms 84 
compatible with anaphylaxis or an IgE-mediated reaction at any time in the past (e.g. urticaria, 85 
angioedema, shortness of breath or hypotension); 2) History of non-severe immediate (<1 hour) 86 
or accelerated (> 1 hour to <36 hours) within the past 5 years (e.g. isolated urticaria, 87 














single dose challenge.  A single dose TMP-SMX (80-40 mg) challenge was administered if there 89 
was a history of non-severe delayed reactions without multiple features consistent with IgE 90 
mediated reaction, non-severe immediate reaction (< 1 hour) greater than 5 years ago, non-severe 91 
accelerated reaction (> 1 hour to < 36 hours) greate  than 5 years ago, or unknown, remote 92 
history (Table E1, available in this article’s Online Repository at www.jaci-inpractice.org).  93 
Patients were monitored for 2 hours after each full strength challenge dose in clinic for any 94 
immediate reaction and were contacted by phone 24-hours after challenge to follow-up any 95 
delayed reaction.  Oral challenge success was defined by the absence of any symptoms during 96 
the observed challenge and 24-hour follow up period.  Oral challenge success resulted in the 97 
removal of the “sulfa” or TMP-SMX allergy label from the chart and patient education that 98 
TMP-SMX could now be used in their clinical care.  99 
 100 
Charts were reviewed for patient demographics (age, sex and race), time between index reaction 101 
and challenge, index reaction history (immediate, delayed, unknown), indication for consult 102 
(multi-drug allergy, anticipated need for treatment, need for prophylaxis, or infection without 103 
other options), co-morbidities (HIV, diabetes, MRSA, and transplant), nature of initial label 104 
(TMP-SMX or unspecified sulfa), and type of challeng  performed (single or two dose). Follow-105 
up assessment to determine tolerance of any subsequent TMP-SMX treatments was performed 106 
by chart review, email survey and telephone survey.  In follow up, patients were asked if they 107 
had taken TMP-SMX for treatment and if an adverse drug reaction was experienced. 108 
 109 
The relationship between age, sex, race, HIV status, reported reaction history and time since 110 














test, Wilcoxon rank-sum tests, and univariate logistic regression. These covariates were selected 112 
a priori for their potential as predictors of challenge failure based upon clinical experience 113 
during the performance of the challenges.  A multivariable logistic regression was performed to 114 
adjust for confounding amongst these covariates and utilized 10 degrees of freedom in a total 115 
sample size of 204 patients.  116 
 117 
The demographic and clinical characteristics of the 204 patients are described in Table 1.  Of 118 
204 patients, 195 (95.6%) were HIV non-infected and9 (4.4%) were HIV infected (Figure 1).  119 
Oral challenge was tolerated by 191/204 (94%) patients; with 171/179 (96%) of single dose and 120 
20/25 (80%) of two dose challenges tolerated.  Of patients with a TMP-SMX allergy or 121 
unspecified “sulfa” allergy, 89% (97/109) and 98.9% (94/95) tolerated a single or two dose 122 
challenge, respectively.  Of the 13 patients who met th  definition for oral challenge failure, 123 
reactions were non-severe (Table E2, available in this article’s Online Repository at www.jaci-124 
inpractice.org). 125 
    126 
By index history, 3/23 (13%) of patients with an immediate hypersensitivity history failed oral 127 
challenge, compared to 9/106 (8.5%) with a non-severe d layed history or an unknown history 128 
1/75 (1%), Fisher’s exact test p-value=0.03. A “non-immediate” index reaction history (defined 129 
by either a non-severe delayed or unknown history of original sulfa reaction), showed a reduced 130 
risk of challenge failure compared to a history consistent with an immediate reaction, with an 131 
unadjusted odds ratio (OR) 0.36 (95% CI 0.15, 0.86), p =0.02.  By nature of initial label, 12/109 132 
(11%) of patients with a TMP-SMX allergy label failed oral challenge compared to 1/95 (1%) 133 














challenge, 8/179 (5%) failed compared to 5/25 (20%) of two dose challenge patients, p-135 
value=0.01.  Of the 25 patients that underwent a two dose challenge, 8/25 (32%) patients had an 136 
immediate index reaction history, including 2 of reported anaphylaxis, 16/25 (64%) had a 137 
delayed index reaction history, and 1/25 (4%) had an unknown history (Table E3, available in 138 
this article’s Online Repository at www.jaci-inpractice.org).  37 patients did not know the 139 
amount of time elapsed since their original reaction, but in patients who could provide this 140 
information, significantly more time had elapsed since original reaction in patients who passed 141 
oral challenge (median 20 years, interquartile range [10, 40]), versus failed (median 3 years, 142 
interquartile range [1, 10]), Wilcoxon-rank sum p-value <0.005. In univariate logistic regression, 143 
a one-year increase in time since reported reaction was associated with a decreased risk of oral 144 
challenge failure, with an unadjusted OR 0.87 (95% CI 0.80, 0.96), p =0.005. 145 
 146 
In our a priori multivariable adjusted logistic regssion model including age, sex, race, HIV 147 
status, time since index reaction, and reaction history, time since reaction was significantly 148 
associated with reduced risk of challenge failure, adjusted OR 0.88 per year (95% CI 0.80, 0.97, 149 
p-value =0.01 (Figure E1, available in this article’s Online Repository at ww.jaci-150 
inpractice.org).  A “non-immediate” history was also associated with reduction in the risk of 151 
challenge failure 0.26 (95% CI 0.06, 1.10) p =0.05.  152 
 153 
Of the 52/191 (27%) challenge negative patients whorep rted subsequent TMP-SMX treatment 154 
during follow-up surveys, 43/52 (83%) patients tolerat d all of their subsequent TMP-SMX 155 














events leading to treatment cessation, all of which were mild (Table E4, available in this 157 
article’s Online Repository at www.jaci-inpractice.org). 158 
 159 
A limitation of our study is that it is retrospective, making it potentially difficult to capture the 160 
true number of patients who have received TMP-SMX treatment post-challenge. We addressed 161 
this by using phone and email surveys.  It is also possible that some patients labeled with “sulfa” 162 
antibiotic allergy or oral challenge failures were not a result of hypersensitivity reactions to 163 
sulfamethoxazole but rather trimethoprim alone.7  In addition, 2 patients reported as having 164 
diagnosed anaphylaxis passed two dose oral challenge, a d overall 5 patients who had immediate 165 
histories potentially compatible with anaphylaxis as characterized by immediate reactions with 166 
multisystem involvement were challenged.  It is notable that all 4 of the 5 patients who passed 167 
oral challenge had reactions of remote or unknown latency, and the one patient who failed had an 168 
index reaction less than 1 year from challenge (Table E3, available in this article’s Online 169 
Repository at www.jaci-inpractice.org).  The generalizability of this approach warrants further 170 
study; however, at present, it seems prudent that desensitization be the approach for patients with 171 
a history compatible with anaphylaxis.  Although our n mbers are small, our data also suggests 172 
that patients with a remote history of anaphylaxis (i.e. > 5 years) will be much less likely to react 173 
than those with more recent reactions.  Further, our study supports the use of oral challenge in 174 
patients with a non-severe immediate reaction history; however, the safety of this approach is 175 
limited by the low sample size of patients with an immediate reaction history, 23/204 (11%).  176 
HIV status has been described as an independent risk factor for sulfonamide antibiotic allergy, 177 
for which desensitization approaches have been shown t  be effective.8-9  A previous study also 178 














TMP-SMX will be tolerant.9  Our study supported an oral challenge failure ratin HIV infected 180 
patients of 2/9 (22.2%) (Table 1) which is similar to the rate observed by larger HIV specific 181 
cohorts.9  A major aim of our study was to demonstrate the saf ty and efficacy of single dose 182 
oral challenge with TMP-SMX in non-HIV infected patients and subsequent tolerance of 183 
sulfonamide antibiotics, which we accomplished.  184 
 185 
This is the first study that reports on the safety of TMP-SMX single dose or two dose oral 186 
challenges in predominantly non-HIV-infected patients with “sulfa” antibiotic allergy labels that 187 
were inconsistent with severe delayed cutaneous reactions.  We show that 89% of patients with a 188 
TMP-SMX allergy and 98.9% of those with an unspecifi d “sulfa” antibiotic label can safely 189 
receive a single or two dose oral TMP-SMX challenge.  Further, in patients who undergo future 190 
treatment with TMP-SMX after challenge, the majority (83%) will tolerate it uneventfully, and 191 
for those with a reaction on oral challenge, they experience only mild symptoms. In the past, 192 
desensitization or multiple dose graded challenge has been the proposed strategy for patients 193 
who had a need for sulfa antimicrobials.  Our study supports TMP-SMX single dose or graded 2-194 
dose oral challenge as a safe, pragmatic, efficacious approach to the patient with a non-severe 195 
delayed reaction history, which is the most common clinical phenotype associated with TMP-196 
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Figure Legends: 253 
 254 
Figure 1: Flowchart of the study.  Choice of challenge (single-dose or two-dose) was determined 255 
by reaction history.  Abbreviations: DHR= drug hypersensitivity reaction; HIV= human 256 
























































Total no. of patients 
     
204 191 (93.6) 13 (6.4)  
Age 62 [48, 70] 62 [50, 70] 48 [31, 61] 0.03 
Time since reaction in years (**n=167, with n=37 missing) 20 [9, 39] 20 [10, 40] 3 [1, 10] <0.0005 
Sex 
    Female 













    White 
    Black 
    Unknown 


















Index reaction history 
    Delayed symptoms 
    Unknown 















Indication for Consult 
    Multi-drug allergy 
    Anticipated need for treatment 
    Need for prophylaxis 



















    Non-HIV infected 












    No Diabetes 








    No Transplant 








Nature of initial label 
    Trimethoprim-sulfamethoxazole 












Type of challenge (selected/dependent upon index reaction history) 
    Single dose 












Comparisons between passage versus failure of oral challenge stratified by categorical predictors was performed using two-sided Fisher’s 

















Clinical manifestation of the 
suspected DHR when patients 
retreated
Patients retreated with TMP-SMX 
after negative testing
Oral challenge success rate
HIV status











































Table E1. Criteria for single or two dose TMP-SMX oral challenge and exclusion 
Challenge 
Type 
Criteria Dose(s) Follow-up 
Single Dose Non-severe delayed reactions without multiple features consistent with IgE mediated 
     reaction 
Non-severe immediate (e.g. isolated urticaria, maculopapular rash, or gastrointestinal symptoms)   
     reaction (< 1 hour) greater than 5 years ago 
Non-severe accelerated reaction (> 1 hour to < 36 hours) greater than 5 years ago 
Unknown, remote history 
TMP-SMX 80-400mg 2 hour observation in clinic after full dose 
24 hour phone call after full dose 
Two Dose Non-severe immediate reaction (< 1 hour) within the past 5 years 
Non-severe accelerated reaction (> 1 hour but < 36 hours) within the past 5 years 
Anaphylaxis at any time point in the past 
Multiple (2 or more) features potentially compatible with IgE mediated reaction at any time point   
     in the past  
• Urticaria 
• Angioedema 
• Shortness of breath 
• Hypotension 
Significant patient anxiety surrounding single dose challenge 
TMP-SMX 8-40mg 
TMP-SMX 80-400mg 
1 hour observation in clinic after first dose 
2 hour observation in clinic after second, full dose 
24 hour phone call after second, full, dose 
 
Excluded Stevens-Johnson syndrome 
Toxic epidermal necrolysis 
Drug rash with eosinophilia and systemic symptoms 
Acute generalized exanthematous pustulosis 
Drug induced nephritis 

































1 Delayed 2 Negative Single Rash starting 6 to 8 hours after challenge 0 Delayed 
2 Delayed 1 Negative Single Erythema of the face, neck, chest, and abdomen 8 hours after challenge 0 Delayed 
3 Delayed ? Negative Single Pruritus 30 minutes after challenge dose 0 Immediate 
4 Unknown ? Negative Single Urticaria 1 Delayed 
5 Delayed 9 Negative Single Pruritus 10 minutes after challenge dose 0 Immediate 
6 Delayed 9 Negative Single Low-grade fever, headache, and myalgias without rash 6 hours after challenge 0 Delayed 
7 Immediate 1 Negative Two Urticaria 15 minutes after taking second challenge dose 0 Immediate 
8 Immediate 10 Negative Single Urticaria 30 minutes after challenge dose 0 Immediate 
9 Delayed 14 Negative Two Fever, nausea, vomiting 2 hours after second challenge dose; required observation admission 0 Delayed 
10 Delayed 3 Positive Two Left arm pain and malaise without fever or rash 30 minutes after second challenge dose 0 Immediate 
11 Delayed 15 Negative Single Fever without rash 1 hour after challenge dose 0 Immediate 
12 Immediate 0 Negative Two Throat itching and chest tightness 30 minutes after second challenge dose 0 Immediate 



























1 Delayed Urticaria and face/lip swelling after 7 days 0 TMP-SMX Negative Passed 
2 Delayed Swelling of hands/feet after 12 hours 45 Unspecified sulfa Negative Passed 
3 Delayed Maculopapular rash, fever ? Unspecified sulfa Negative Passed 
4 Immediate Urticaria, shortness of breath* 38 Unspecified sulfa Negative Passed 
5 Immediate Urticaria, angioedema, shortness of breath* 47 Unspecified sulfa Negative Passed 
6 Delayed Urticaria after 7 days  1 TMP-SMX Negative Passed 
7 Delayed Urticaria after 14 days 1 TMP-SMX Negative Passed 
8 Delayed Maculopapular rash after 2 days 11 TMP-SMX Negative Passed 
9 Delayed Shortness of breath, throat swelling after 2 days 15 Unspecified sulfa Negative Passed 
10 Delayed Urticaria and facial swelling after 12 hours 27 Unspecified sulfa Negative Passed 
11 Delayed Urticaria 2 years into taking for PJP prophylaxis 25 TMP-SMX Positive Passed 
12 Immediate Urticaria 1 TMP-SMX Negative Failed 
13 Delayed Urticaria after several doses 8 TMP-SMX Negative Passed 
14 Delayed Fever, nausea, vomiting, and hypotension after second dose 14 TMP-SMX Negative Failed 
15 Delayed Urticaria after third dose 20 TMP-SMX Negative Passed 
16 Immediate Anaphylaxis (urticaria, shortness of breath) 47 Unspecified sulfa Negative Passed 
17 Delayed Fever, arm pain, vomiting, and malaise after two days 3 TMP-SMX Positive Failed 
18 Delayed Urticaria after third dose 12 TMP-SMX Negative Passed 
19 Immediate Shortness of breath, chest tightness* 0 TMP-SMX Negative Failed 
20 Delayed Urticaria, lip swelling after 5 days of PJP prophylaxis 0 TMP-SMX Positive Failed 
21 Immediate Throat tightness, palpitations 15 Unspecified sulfa Negative Passed 
22 Delayed Urticaria, face/lip/tongue swelling after three days 0 TMP-SMX Negative Passed 
23 Unknown Reaction within 1 day 6 TMP-SMX Negative Passed 
24 Immediate Anaphylaxis (no symptom description available) ? TMP-SMX Negative Passed 
25 Immediate Urticaria, lip swelling 1 TMP-SMX Negative Passed 















Table E4. Symptoms attributed to TMP-SMX during subsequent courses of treatment which led to cessation of treatment  
Patient 
no. 






1 Nausea 3 Non-allergic Yes 
2 Rash (tolerated 3 retreatment courses previously) 2 Delayed Yes 
3 Mouth ulcers (tolerated 7 retreatment courses 
previously) 
1 Delayed Yes 
4 Rash 10 Delayed Yes 
5 Back pain 7 Non-allergic Yes 
6 Mouth and lip tingling 2 Non-allergic Yes 
7 Rash 6 Delayed Yes 
8 Cough 7 Non-allergic Yes 



























Figure E1: Probability of oral challenge failure and time from index reaction (years) in a logistic 
model adjusted for age, sex, ethnicity, HIV status, and index reaction history. 
Abbreviations: TMP-SMX= trimethoprim-sulfamethoxazole 
 
